Volume 99, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



The efficacies of 3-day regimens of artemether–lumefantrine (AL), artesunate–amodiaquine (AA), and dihydroartemisinin–piperaquine (DHP) were evaluated in 910 children < 5 years old with uncomplicated malaria from six geographical areas of Nigeria. Parasite positivity 1 day and Kaplan–Meier estimated risk of persistent parasitemia 3 days after therapy initiation were both significantly higher, and geometric mean parasite reduction ratio 1 day after treatment initiation (PRRD1) was significantly lower in AL-treated children than in AA- and DHP-treated children. No history of fever, temperature > 38°C, enrollment parasitemia > 75,000 μL, and PRRD1 < 5,000 independently predicted persistent parasitemia 1 day after treatment initiation. Parasite clearance was significantly faster and risk of reappearance of asexual parasitemia after initial clearance was significantly lower in DHP-treated children. Overall, day 42 polymerase chain reaction–corrected efficacy was 98.3% (95% confidence interval [CI]: 96.1–100) and was similar for all treatments. In a non-compartment model, declines of parasitemias were monoexponential with mean terminal elimination half-life of 1.3 hours and unimodal frequency distribution of half-lives. All treatments were well tolerated. In summary, all three treatments evaluated remain efficacious treatments of uncomplicated malaria in young Nigerian children, but DHP appears more efficacious than AL or AA.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Carrara VI, 2009. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One 4: e4551. [Google Scholar]
  2. Dondorp AM, 2009. Artemisinin resistance in Plasmodium falciparum. N Engl J Med 361: 455467. [Google Scholar]
  3. Noedl H, 2010. Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in southeast Asia. Clin Infect Dis 51: e82e89. [Google Scholar]
  4. Phyo AP, 2012. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 379: 19601966. [Google Scholar]
  5. Phyo AP, 2016. Declining efficacy of artemisinin combination therapy against P. falciparum malaria on the Thai-Myanmar border (2003–2013): the role of parasite genetic factors. Clin Infect Dis 63: 784791. [Google Scholar]
  6. World Health Organization, 2015. Status Report on Artemisinin and ACT Resistance. Geneva, Switzerland: WHO. Available at: http://www.who.int/malaria/publications/atoz/update-artemisinin-resistance-sep2015/en/. Accessed September 1, 2016.
  7. Imwong M, 2017. The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong Subregion: a molecular epidemiology observational study. Lancet Infect Dis 17: 491497. [Google Scholar]
  8. Maiga AW, 2012. No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Am J Trop Med Hyg 87: 2328. [Google Scholar]
  9. Bosman A, Mendis KN, , 2007. A major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies. Am J Trop Med Hyg 77 (Suppl 6): 193197. [Google Scholar]
  10. Borrmann S, 2011. Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. PLoS One 6: e26005. [Google Scholar]
  11. Ashley EA, Tracking Resistance to Artemisinin Collaboration (TRAC) , 2014. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 371: 411423. [Google Scholar]
  12. Ouattara A, 2015. Polymorphisms in the K13-propeller gene in artemisinin-susceptible Plasmodium falciparum parasites from Bougoula-Hameau and Bandiagara, Mali. Am J Trop Med Hyg 92: 12021206. [Google Scholar]
  13. Lu P, 2017. Emergence of indigenous artemisinin-resistant Plasmodium falciparum in Africa. N Engl J Med 376: 991993. [Google Scholar]
  14. World Health Organization, 2010. Guidelines for the Treatment of Malaria, 2nd edition. Geneva, Switzerland: WHO.
  15. World Health Organization, 2015. Guidelines for the Treatment of Malaria, 3rd edition. Geneva, Switzerland: WHO.
  16. Zwang J, 2009. Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS One 4: e6358. [Google Scholar]
  17. Nji AM, 2015. Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children. Malar J 14: 27. [Google Scholar]
  18. Leang R, Barrette A, Bouth DM, Menard D, Abdur R, Duong S, Ringwald P, , 2013. Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Chemother 57: 818826. [Google Scholar]
  19. Wang Y, Yang Z, Yuan G, Parker D, Lee M-C, Yan G, Fan Q, Xiao Y, , 2015. Clinical efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria at the China-Myanmar Border. Am J Trop Med Hyg 93: 577583. [Google Scholar]
  20. Sagara I, 2018. Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. Lancet 391: 13781390. [Google Scholar]
  21. Oguche S, 2014. Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five year-old Nigerian children. Am J Trop Med Hyg 91: 925935. [Google Scholar]
  22. World Health Organization, 2000. Severe falciparum malaria. Trans R Soc Trop Med Hyg 94 (Suppl 1): 190. [Google Scholar]
  23. World Health Organization, 2014. Severe malaria. Trop Med Int Health 19 (Suppl 1): 7131. [Google Scholar]
  24. World Health Organization, 2003. Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated Falciparum Malaria. WHO/HTM/RBM/2003.50. Geneva, Switzerland: WHO.
  25. Happi CT, Gbotosho GO, Sowunmi A, Falade CO, Akinboye DO, Gerena L, Kyle DE, Milhous W, Wirth DE, Oduola AM, , 2004. Molecular analysis of Pasmodium falciparum recrudescent malaria infection in children treated with chloroquine in Nigeria. Am J Trop Med Hyg 70: 2026. [Google Scholar]
  26. World Health Organization, 2009. Methods for Surveillance for Antimalarial Drug Efficacy. Geneva, Switzerland: WHO.
  27. Sowunmi A, Akano K, Ayede AI, Adewoye EO, Ntadom G, Fatunmbi B, Gbotosho GO, Folarin OA, Happi CT, , 2017. Early rising asexual parasitaemia in Nigerian children following a first dose of artemisinin-based combination treatments of falciparum malaria. BMC Infect Dis 17: 110. [Google Scholar]
  28. Gbotosho GO, Sowunmi A, Happi CT, Okuboyejo TM, , 2011. Therapeutic efficacies of artemisinin-based combination therapies in Nigerian children with uncomplicated falciparum malaria during five years of adoption as first-line treatments. Am J Trop Med Hyg 84: 936943. [Google Scholar]
  29. Anon, 2016. Epi Info Version 7. A Word Processing Data Base and Statistics Program for Public Health on IBM-Compatible Microcomputers. Atlanta, GA: Centers for Disease Control and Prevention.
  30. Anon, 2013. International Business Machine (IBM) Corporation 2013. SPSS for Windows Release 22.0 (Standard Version). Armonk, NY: IBM Corp.
  31. World Health Organization, 2017. World Malaria Report. Geneva, Switzerland: WHO.
  32. Stepniewska K, 2010. In vivo parasitological measures of artemisinin susceptibility. J Infect Dis 201: 570579. [Google Scholar]
  33. Federal Ministry of Health, 2005. National Antimalarial Treatment Guideline. Abuja, Nigeria: Federal Ministry of Health.
  34. Nosten F, White NJ, , 2007. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg 77 (Suppl 6): 181192. [Google Scholar]
  35. Kyaw MP, 2013. Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. PLoS One 8: e57689. [Google Scholar]
  36. Olliaro P, Mussano P, , 2003. Amodiaquine for treating malaria. Cochrane Database Syst Rev 2: CD000016. [Google Scholar]
  37. Tarning J, Ashley EA, Lindegardh N, Stepniewska K, Phaiphun L, Day NPJ, McGready R, Ashton M, Nosten F, White NJ, , 2008. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob Agents Chemother 52: 10521061. [Google Scholar]
  38. Tarning J, Thana P, Phyo AP, Lwin KM, Hanpithakpong W, Ashley EA, Day NPJ, Nosten F, White NJ, , 2014. Population pharmacokinetics and antimalarial pharmacodynamics of piperaquine in patients with Plasmodium vivax malaria in Thailand. CPT Pharmacometrics Syst Pharmacol 3: e132. [Google Scholar]
  39. Hoglund RM, 2017. Population pharmacokinetic properties of piperaquine in falciparum malaria: an individual participant data meta-analysis. PLoS Med 14: e1002212. [Google Scholar]
  40. Michael OS, Gbotosho GO, Folarin OA, Okuboyejo T, Sowunmi A, Oduola AM, Happi CT, , 2010. Early variations in Plasmodium falciparum dynamics in Nigerian children after treatment with two artemisinin-based combinations: implications on delayed parasite clearance. Malar J 9: 335. [Google Scholar]
  41. Sowunmi A, Okuboyejo TM, Gbotosho GO, Happi CT, , 2012. Early changes in Plasmodium falciparum asexual and sexual populations in children with acute infections following treatment with artemisinin-based combination drugs. Mal Chemother Ctrl Elim 1: 235498. [Google Scholar]
  42. White NJ, , 2016. Can new treatment development combat resistance in malaria? Expert Opin Pharmacother 17: 13031307. [Google Scholar]

Data & Media loading...

  • Received : 08 Feb 2018
  • Accepted : 08 May 2018
  • Published online : 25 Jun 2018

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error